Skip to main content

Table 1 Baseline characteristics of patients admitted to the ICU with suspected septic shock (n = 508) and comparison between patients with early-confirmed septic shocks (EC-SS) and other patients (non EC-SS)

From: Septic shock with no diagnosis at 24 hours: a pragmatic multicenter prospective cohort study

  All patients (n = 508) EC-SS (n = 374) Non EC-SS (n = 134) P
Age and gender
 Age, years 68 (59–79) 67 (58–80) 68 (61–78) 0.81
 Male gender 297 (58) 219 (59) 78 (58) >0.99
Comorbidities
 Chronic respiratory disease 21 (4) 17 (5) 4 (3) 0.44
 Chronic heart failure 34 (7) 22 (6) 12 (9) 0.22
 Chronic kidney disease 46 (9) 33 (9) 13 (10) 0.76
 Cirrhosis 49 (10) 35 (9) 14 (10) 0.71
 Recent malignant hemopathy 34 (7) 27 (7) 7 (5) 0.43
 Recent cancer 63 (12) 43 (11) 20 (15) 0.30
 Diabetes mellitus 132 (26) 87 (23) 45 (34) 0.019
 HIV infection 17 (3) 11 (3) 6 (4) 0.40
 Obesity 71 (14) 54 (14) 17 (13) 0.62
 Cerebrovascular disease 55 (11) 37 (10) 18 (13) 0.26
 Immunosuppressive therapy 54 (11) 41 (11) 13 (10) 0.68
 Immunosuppression statusa 132 (26) 95 (25) 37 (28) 0.62
 No coexisting comorbid conditions 154 (30) 119 (32) 35 (26) 0.22
Clinical data within 24 h of inclusion and antibiotic therapy
 Maximal temperature, °C 38.2 (37.3–39.0) 38.4 (37.4 − 39.1) 37.9 (36.9 − 38.6) <0.0001
 Minimal temperature, °C 36.1 (35.2–37.0) 36.2 (35.4–37.0) 36.0 (34.6–36.8) 0.006
 Glasgow Coma Scale 14 (11–15) 15 (12–15) 13 (9–15) 0.002
 SAPS2 58 (47–73) 58 (45–72) 59 (50–75) 0.34
 Delay admission-inclusion, hours 1 (0–6) 2 (0–7) 1 (0–4) 0.33
 Delay inclusion -ATB1, hours 0 (0–1) 0 (0–1) 0 (0–1) 0.28
 Delay inclusion -ATB2, hours 0 (0–2) 0 (0–2) 0 (0–2) 0.59
 Number of ATB administered at 3 h 2 (1–2) 2 (1–2) 2 (1–2) 0.09
 Number of ATB administered at 24 h 2 (2–3) 2 (2–3) 2 (1–3) 0.050
Biological data within 24 h of inclusion
 Leukocyte count, 103.mm−3 16.5 (9.9–24.6) 17.1 (9.8–24.9) 15.9 (9.9–23.0) 0.62
 Platelets count, 103/mm−3 156 (85–243) 156 (81–45) 155 (92–236) 0.72
 C-reactive protein, mg/Lb 166 (87 − 265) 178 (110 − 288) 108 (48–179) <0.0001
 Procalcitonin, ng/mLc 7.6 (1.3–37.9) 19.6 (3.7–56.5) 1.6 (0.7–7.8) <0.0001
 Serum urea, mmol/L 14.0 (8.7–21.7) 13.6 (8.7–20.0) 16.0 (9.1–24.0) 0.16
 Serum creatinine, μmoL/L 187 (114–296) 187 (115–275) 198 (107–347) 0.13
 Prothrombin time, % 58 (41–72) 58 (42–72) 56 (38–72) 0.72
 Arterial lactate, mmol/L 3.5 (2.0–7.0) 3.4 (2.0–6.1) 3.6 (2.0–10.0) 0.13
  1. Categorical variables are expressed as number (%) and continuous variables as median (IQR 25–75). aImmunosuppression status includes patients with HIV or malignant hemopathy or recent cancer, or under immunosuppressive therapy. bValue available for 248 patients. cValue available for 128 patients. ATB antibiotic therapy, h hour, HIV human immunodeficiency virus, SAPS2 Simplified Acute Physiology Score, WBC white blood count